New fused pyrazolopyrimidine derivatives; heterocyclic styling, synthesis, molecular docking and anticancer evaluation

Novel pyrazolopyrimidines and their fused derivatives derived from aminopyrazole moiety as pyrazoloquinazoline, chromenopyrazolopyrimidine, pyrazolopyrimidopyrimidine, pyrazolopyrimidotriazepine and benzoimidazopyrazolopyrimidine were designed, synthesized and evaluated for their anticancer activities. Twenty of the synthesized compounds were tested by the National Cancer Institute (NCI, Bethesda, USA) at a single high dose (10‐5 M). It was found that 5‐amino‐1H‐pyrazole‐4‐carbonitrile derivative, pyrazolo[5,1‐b]quinazoline‐11‐carbonitrile derivative and 1‐amino‐2,4‐dihydro‐5H‐benzo[4,5]imidazo[1,2‐c]pyrazolo[4,3‐e]pyrimidin‐5‐one were own widely selective powerful anticancer activity towards certain cancer cell lines and this also proved through docking studies with cyclooxygenase‐2 (COX‐2) enzyme.